IVB期宫颈癌放化疗联合盆腔放疗可显著延长总生存
该多中心回顾性研究纳入2005-2015年诊断的IVB期宫颈癌患者,比较盆腔放疗联合化疗(WPR+CT)与单纯化疗(CT)的疗效。结果显示WPR+CT组总生存显著延长(41.6 vs 17.6个月,p<0.01),两组并发症发生率无显著差异。
要点
- IVB期宫颈癌化疗基础上加盆腔放疗,总生存显著延长(41.6 vs 17.6个月,p<0.01)。
- 两组输尿管梗阻、阴道出血、盆腔感染、盆腔疼痛及瘘的发生率无显著差异(均p>0.05)。
- 研究为多中心回顾性设计,需进一步研究确定最可能获益的亚组。
核心结论
- 盆腔放疗联合化疗较单纯化疗显著延长IVB期宫颈癌患者总生存(41.6 vs 17.6个月,p<0.01)。
主要发现
- 可分析人群中,中位年龄53岁,72%为鳞癌,82%为FIGO 2或3级肿瘤。
- 盆腔放疗联合化疗组总生存显著长于单纯化疗组(41.6 vs 17.6个月,p<0.01)。
- 两组输尿管梗阻、阴道出血、盆腔感染、盆腔疼痛及瘘的发生率无显著差异(均p>0.05)。
临床怎么用
- 对于IVB期宫颈癌患者,在化疗基础上联合盆腔放疗可能作为初始治疗策略之一,但需进一步研究确定最可能获益的亚组。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chemotherapy is the standard treatment in stage IVB cervical cancer (CC). However, given that many women have a significant pelvic disease burden, whole pelvic radiation (WPR) in addition to chemotherapy for primary treatment may have utility. The aim of this study was to compare the overall survival (OS) and complication rates between women who received both WPR and chemotherapy (CT) versus CT alone in the management of stage IVB CC. METHODS: A multi-institutional, IRB-approved, retrospective review of patients (pts) with stage IVB CC, diagnosed between 2005 and 2015, was performed. Descriptive statistics of the demographic, oncologic, and treatment characteristics were performed. OS was estimated using the Kaplan Meier method. RESULTS: A total of 126 pts met inclusion criteria. Thirty one patients elected for hospice care at diagnosis and were excluded from further analysis. In the remaining population, median age was 53 yrs. The majority (72%) had squamous cell carcinoma and 82% had FIGO grade 2 or 3 tumors. Thirty four patients (35.8%) received WPR in addition to CT as a part of planned primary therapy and 64.2% (n = 61) received CT alone, with 88.2% and 80.3% receiving a cisplatin-based chemotherapy regimen, respectively. The OS was significantly longer in the WPR with CT group (41.6 vs 17.6 mo, p < 0.01). The rates of ureteral obstruction, vaginal bleeding, pelvic infection, pelvic pain, and fistula were not significantly different between the 2 groups (all p > 0.05). CONCLUSION: This study found WPR in addition to CT gives a significant OS benefit. Further study is warranted to determine which subgroups may benefit the most from this novel treatment strategy.
引用
- Perkins V, Moore K, Vesely S, et al. Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2019. PMID: 31810653. doi:10.1016/j.ygyno.2019.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。